CSPC：SYH2059 has received its first clinical trial approval.
In March 2026, SYH2059 Inhalation Powder received a clinical trial tacit approval in China for the indication of pulmonary fibrosis.
SYH2059 is a highly selective phosphodiesterase 4B (PDE4B) inhibitor developed by CSPC Pharmaceutical Group. Preclinical studies have shown that SYH2059 significantly increases pulmonary drug concentration while reducing systemic exposure, thereby decreasing gastrointestinal side effects, with favorable pharmacokinetic characteristics and a high safety window.
In addition to the inhalation powder formulation approved for clinical trial, CSPC Pharmaceutical Group has also developed SYH2059 tablets, which have received clinical trial approval for the indication of interstitial lung disease, including but not limited to idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. CSPC is currently conducting clinical studies in China for SYH2059 tablets in idiopathic pulmonary fibrosis (Phase II) and interstitial lung disease (Phase I), as well as a Phase I study for SYH2059 Inhalation Powder in interstitial lung disease.
Buy SYH2059 from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
